Recordati S.p.A. : Nomination de Gianni Soro au poste de Directeur G?n?ral de la division pharmaceutique en Italie

Milan, le 21 novembre 2006 – Recordati a annoncé la nomination de Gianni Soro au poste de Directeur Général de la division pharmaceutique en Italie. M Soro prend la place du Dr. Andrea Breschi, qui a quitté la société.

Gianni Soro est diplômé d'Économie de l'Université L. Bocconi de Milan et possède une longue et riche expérience dans le secteur pharmaceutique.

Entre 1987 et 1991, il était Directeur Général de Pierrel S.p.A., société chimie pharmaceutique cotée sur le marché italien. Entre 1992 et 2001, M Soro a été Président et Directeur Général de Malesci S.p.A., une filiale du groupe pharmaceutique Menarini. As from 2002 Mr. Soro was Chairman and CEO of Keryos S.p.A., a pharmaceutical company dedicated both to original research and marketing and sales of pharmaceutical specialties.

In addition, Mr. Soro was a member of the Health Ministry's Commission for the pricing of pharmaceuticals from 1977 to 1983 and President of the Commission in 1982 and 1983. He was also President of the Commission for pharmaceutical pricing methodology and a member of other Ministerial Commissions. From 1999 to 2002 Mr. Soro was Vice Chairman of Farmindustria, the Italian pharmaceutical companies association, and from 2000 to 2002 President of the association's Ethics Committee. As from 2004 he is also a non-tenured member of the Faculty of Pharmacy at the University of Siena.

"We are very pleased to have Gianni Soro join the company" declared Giovanni Recordati, Chairman and CEO. "Mr. Soro's extensive experience in the pharmaceutical sector and his proven management skills will be of great value to us in these times of evolution in the pharmaceutical industry both worldwide and in particular in Italy, where we must operate in a continuously changing environment".

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), dedicated to the research, development, manufacturing and marketing of pharmaceuticals, with headquarters in Milan, Italy, operations in the main European countries, and a total staff of over 2,000. A European field force of over 1,000 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research team has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product. Consolidated revenue for 2005 was € 576.1 million, operating income was € 111.1 million and net income was € 64.5 million.

For further information:

Recordati website: www.recordati.com

Investor Relations
Marianne Tatschke
(39)0248787393
e-mail: [email protected]

Media Relations
Claudio Rossetti (Echo Comunicazione d'Impresa)
(39)02 62694736
e-mail: [email protected]

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements.

All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.